Previous 10 | Next 10 |
The stock market's tumble in mid-March was driven by indiscriminate selling caused by an awakening to the possibility of double-digit unemployment and up to a 30% drop in second quarter gross domestic product ((GDP)), coupled with changes in margin requirements resulting in forced liquidation....
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2020 financial results on Wednesday, April 29, 2020. AtriCure will host a conference call ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial have been accepted for presentation in the late-breaking abstract sessions at the Heart Rhyt...
Citing COVID-19 disruptions, AtriCure (NASDAQ: ATRC ) is withdrawing its previously issued financial guidance for 2020. More news on: AtriCure, Inc., Healthcare stocks news, , Read more ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first quarter 2020 and provided updates in response to the COVID-19 pandemic. “Throu...
AtriCure, Inc. (ATRC) Q4 2019 Results Earnings Conference Call February 18, 2020 04:30 PM ET Company Participants Lynn Lewis - Gilmartin Group, Investor Relations Mike Carrel - President and Chief Executive Officer Andy Wade - Chief Financial Officer Conference Call Participan...
Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q4 2019 Earnings Call Feb 18, 2020 , 4:30 p.m. ET Operator Continue reading
AtriCure (NASDAQ: ATRC ): Q4 Non-GAAP EPS of -$0.37 beats by $0.03 ; GAAP EPS of -$0.42 in-line. More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
2019 Worldwide revenue of $230.8 million – an increase of 14.5% year over year 2019 U.S. revenue of $185.8 million – an increase of 14.6% year over year 2019 International revenue of $45.0 million – an increase of 13.9% year over year AtriCure, Inc . ( N...
BTIG Research has restarted coverage on the following: More news on: Abbott Laboratories, Abiomed, Inc., AtriCure, Inc., Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-31 08:00:12 ET Rick Wise from Stifel Nicolaus issued a price target of $26.00 for ATRC on 2024-07-31 06:57:00. The adjusted price target was set to $26.00. At the time of the announcement, ATRC was trading at $22. The overall price target consensus is at $56.00 w...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...